Jeff Yass’s Artelo Biosciences ARTL Stock Holding History

Jeff Yass’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,133	Closed	-$17.8K	–	12603
2025 Q1	$17.8K	Buy	+1,133	New	+$22.8K	﹤0.01%	12133
2022 Q3	–	Sell	-297	Closed	-$25K	–	13111
2022 Q2	$25K	Buy	297 +257	+643%	+$25.3K	﹤0.01%	12295
2022 Q1	$5K	Sell	40 -20	-33%	-$2.3K	﹤0.01%	12816
2021 Q4	$8K	Buy	+60	New	+$11.9K	﹤0.01%	12951

Other funds holding ARTL

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's ARTL Position: Q2 2025 in Review

Jeff Yass sold out of Artelo Biosciences (ARTL) in Q2 2025, closing a stake of 1,133 shares — an estimated $17.8K sold.

Jeff Yass first reported a position in ARTL in Q4 2021 and held it in 4 quarters. The position peaked at $25K in Q2 2022. 6 funds tracked by Wall St. Rank hold ARTL as of Q2 2025.

Jeff Yass reported no remaining Artelo Biosciences position as of Q2 2025 after selling out during the quarter.
Jeff Yass sold 1,133 Artelo Biosciences shares in Q2 2025, an estimated $17.8K.
Jeff Yass first reported a position in Artelo Biosciences in Q4 2021 and held it in 4 quarters.
Jeff Yass's Artelo Biosciences position peaked at $25K in Q2 2022.
6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.